Neurorx, Inc. Receives A Notice of Patent Allowance Covering the Composition of Matter for Its Drug Nrx-101
January 08, 2020 at 08:14 am EST
Share
NeuroRx, Inc. announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need that results in the death of more than 25,000 Americans each year. The allowance is based on US Patent Application 15/987,932 entitled: Composition and Method for Treatment of Depression and Psychosis in Humans. The inventor, Prof. Daniel Javitt, Ph.D., M.D., is co-founder of NeuroRx and was among the first to report the role of the NMDA receptor in psychiatric disease. NRX-101, an NMDA-targeted antidepressant, is a fixed-dose combination of D-cycloserine and lurasidone and was awarded Fast Track and Breakthrough Therapy Designation by the US FDA. The drug is currently undergoing phase 3 clinical trials under an FDA Special Protocol Agreement.
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
NRX PHARMACEUTICALS, INC. 
